Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial is studying two different schedules of docetaxel and bortezomib to compare how
well they work in treating patients with progressive or recurrent non-small cell lung cancer.
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
docetaxel together with bortezomib may kill more tumor cells